CN120309734A - 人源化补体5a受体1抗体和其使用方法 - Google Patents

人源化补体5a受体1抗体和其使用方法

Info

Publication number
CN120309734A
CN120309734A CN202510469073.3A CN202510469073A CN120309734A CN 120309734 A CN120309734 A CN 120309734A CN 202510469073 A CN202510469073 A CN 202510469073A CN 120309734 A CN120309734 A CN 120309734A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
acid sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510469073.3A
Other languages
English (en)
Chinese (zh)
Inventor
K·维斯瓦纳坦
B·布思
B·拉马克里什南
A·沃拉科特
G·巴布科克
Z·施赖弗
L·奥林斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Priority claimed from CN202280017903.3A external-priority patent/CN117377688A/zh
Publication of CN120309734A publication Critical patent/CN120309734A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202510469073.3A 2021-01-13 2022-01-13 人源化补体5a受体1抗体和其使用方法 Pending CN120309734A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163137089P 2021-01-13 2021-01-13
US63/137,089 2021-01-13
US202163274748P 2021-11-02 2021-11-02
US63/274,748 2021-11-02
PCT/US2022/012317 WO2022155340A1 (en) 2021-01-13 2022-01-13 Humanized complement 5a receptor 1 antibodies and methods of use thereof
CN202280017903.3A CN117377688A (zh) 2021-01-13 2022-01-13 人源化补体5a受体1抗体和其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280017903.3A Division CN117377688A (zh) 2021-01-13 2022-01-13 人源化补体5a受体1抗体和其使用方法

Publications (1)

Publication Number Publication Date
CN120309734A true CN120309734A (zh) 2025-07-15

Family

ID=80225529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202510469073.3A Pending CN120309734A (zh) 2021-01-13 2022-01-13 人源化补体5a受体1抗体和其使用方法

Country Status (12)

Country Link
US (4) US11912781B2 (https=)
EP (1) EP4277931A1 (https=)
JP (1) JP2024502863A (https=)
KR (1) KR20230142831A (https=)
CN (1) CN120309734A (https=)
AU (1) AU2022207985A1 (https=)
CA (1) CA3173944A1 (https=)
IL (1) IL304249A (https=)
MX (1) MX2023008302A (https=)
TW (1) TW202246331A (https=)
WO (1) WO2022155340A1 (https=)
ZA (1) ZA202306343B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI869528B (zh) * 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US8071096B2 (en) 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
WO2004043223A2 (en) 2002-11-05 2004-05-27 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
WO2004082568A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
WO2005050199A1 (en) 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein- coupled receptor 77 (gpr77)
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
JP2010501165A (ja) 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
ES2570153T3 (es) 2006-08-22 2016-05-17 Novo Nordisk As Anticuerpos anti-C5aR con propiedades mejoradas
WO2009005651A2 (en) 2007-06-29 2009-01-08 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
EP2229410A4 (en) 2007-12-05 2012-07-04 Massachusetts Inst Technology AGLYCOSYLATED IMMUNOGLOBULIN MUTANES
RU2010138612A (ru) * 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
US8940299B2 (en) 2008-02-28 2015-01-27 Case Western Reserve University Method of treating cancer
US20180256646A1 (en) 2008-03-06 2018-09-13 Case Western Reserve University Compositions and methods for modulating toll like receptor signal
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11130801B2 (en) 2011-01-13 2021-09-28 Case Western Reserve University Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
US8952132B2 (en) 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
JP6454547B2 (ja) 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
AU2013289883B2 (en) 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
JP2016523829A (ja) 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
KR102332303B1 (ko) 2013-05-31 2021-11-26 자임워크스 인코포레이티드 감소되거나 침묵화된 효과기 기능을 갖는 이종다량체
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
US20180243370A1 (en) 2015-09-14 2018-08-30 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
CN106957366B (zh) 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
KR20190057083A (ko) 2016-10-06 2019-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 공정 불순물에 대한 결합이 감소된 항체
FR3058159B1 (fr) 2016-10-28 2022-02-25 Lab Francais Du Fractionnement Variants de polypeptide fc presentant une demi-vie augmentee
EP3576793A4 (en) 2017-02-06 2021-03-31 Dana Farber Cancer Institute, Inc. COMPOSITIONS AND PROCEDURES FOR ENHANCING ANTIBODY-MEDIATED RECEPTOR SIGNALING
CN113603780B (zh) 2017-03-28 2022-07-01 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
CA3120566C (en) 2017-04-07 2023-12-12 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life
US20200148779A1 (en) 2017-05-25 2020-05-14 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
TWI786132B (zh) 2017-06-23 2022-12-11 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
CA3078732A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163
CA3274059A1 (en) * 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
CN117924477A (zh) 2017-12-19 2024-04-26 洛克菲勒大学 具有改进的效应子功能的人IgG Fc结构域变体
US20210070860A1 (en) 2018-03-21 2021-03-11 Dana-Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
US20200376135A1 (en) 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
JP7617012B2 (ja) 2019-03-14 2025-01-17 モルフォシス・アーゲー Ｃ５ａＲを標的とする抗体
MA55818A (fr) * 2019-04-29 2022-03-16 Immunogen Inc Anticorps et immunoconjugués de fr-alpha biparatopique
US20220306735A1 (en) 2019-08-30 2022-09-29 University Of Kansas Compositions including igg fc mutations and uses thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2021180063A1 (en) 2020-03-09 2021-09-16 I-Mab Biopharma Co., Ltd. Methods for detecting and quantifying biological modifications in antibodies
PH12022552556A1 (en) 2020-03-27 2024-04-22 Inflarx Gmbh Inhibitors of c5a for the treatment of corona virus infection
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20220356263A1 (en) 2022-11-10
US12264203B2 (en) 2025-04-01
US20240392029A1 (en) 2024-11-28
AU2022207985A1 (en) 2023-07-06
MX2023008302A (es) 2023-09-25
IL304249A (en) 2023-09-01
TW202246331A (zh) 2022-12-01
US20250002603A1 (en) 2025-01-02
US20250171555A1 (en) 2025-05-29
EP4277931A1 (en) 2023-11-22
JP2024502863A (ja) 2024-01-23
US12227587B2 (en) 2025-02-18
KR20230142831A (ko) 2023-10-11
WO2022155340A1 (en) 2022-07-21
CA3173944A1 (en) 2022-07-21
ZA202306343B (en) 2024-03-27
US11912781B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
US20210347904A1 (en) Antibodies against tl1a and uses thereof
EP2718322B1 (en) Therapeutic antibodies
JP7612658B2 (ja) 抗ｍｓ４ａ４ａ抗体、及びその使用方法
KR20110082172A (ko) Ｉｌ-1ｒ1에 대한 결합 성분
US20250171555A1 (en) Humanized complement 5a receptor 1 antibodies and methods of use thereof
AU2020281378B2 (en) Anti-TrkA antibodies and uses thereof
JP2025098167A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
TW202003570A (zh) 抗trem-1抗體及其用途
CN115867352A (zh) 抗α4β7抗体
CN119285771A (zh) 抗vegfr1抗体及其用途
CN118546253A (zh) 针对人trem-1的抗体及其用途
US20250188186A1 (en) Ph-selective antibody fc domains
WO2024206161A1 (en) Abeta-targeting proteins and methods of use
HK40128818A (zh) 人源化补体5a受体1抗体和其使用方法
CN117377688A (zh) 人源化补体5a受体1抗体和其使用方法
EA052464B1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К РЕЦЕПТОРУ КОМПОНЕНТА КОМПЛЕМЕНТА 5a ТИПА 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP4644413A1 (en) Binding agents having altered fc-mediated effector functions
US20250122286A1 (en) Antibody optimization
TW202607021A (zh) 結合ｔｓｌｐ之抗體及使用方法
CN118103404A (zh) 抗vegfr1抗体及其用途
JP2025524927A (ja) カンナビノイド受容体１型結合タンパク質及びその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40128818

Country of ref document: HK